• Concerns about an increased risk of neuropsychiatric adverse events (NPAEs) during exposure to Dolutegravir (DTG) have been recently raised in observational studies[1-5] • Historically, Efavirenz (EFV) was largely associated to a higher risk of NPAEs with an increased rate of discontinuations for toxicity compared with other antiretrovirals[6] • Despite this common toxicity profile, comparisons of NPAEs’ risk between DTG and EFV-based regimens are limited. A large comparative randomized trial showed a lower rate of NPAEs with fewer discontinuations in ART-naïve patients starting DTG compared to those starting EFV[7,8] . However, direct comparisonsin real-life setting are lacking.
Titolo: | Comparative neuropsychiatric toxicity profile of dolutegravir versus efavirenz versus other antiretroviral third drugs used either in first-line or switching antiretroviral therapies (ART): data from ICONA Foundation Study Cohort |
Autori: | PELLICANO', Giovanni Francesco [Membro del Collaboration Group] |
Data di pubblicazione: | 2019 |
Rivista: | |
Abstract: | • Concerns about an increased risk of neuropsychiatric adverse events (NPAEs) during exposure to Dolutegravir (DTG) have been recently raised in observational studies[1-5] • Historically, Efavirenz (EFV) was largely associated to a higher risk of NPAEs with an increased rate of discontinuations for toxicity compared with other antiretrovirals[6] • Despite this common toxicity profile, comparisons of NPAEs’ risk between DTG and EFV-based regimens are limited. A large comparative randomized trial showed a lower rate of NPAEs with fewer discontinuations in ART-naïve patients starting DTG compared to those starting EFV[7,8] . However, direct comparisonsin real-life setting are lacking. |
Handle: | http://hdl.handle.net/11570/3147228 |
Appare nelle tipologie: | 14.d.1 Abstract in Atti di convegno |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
PE32-10.pdf | Altro materiale allegato (es. Copertina, Indice, Materiale supplementare, Brevetti, Spin off, Start up, etc.) | Tutti i diritti riservati (All rights reserved) | Open Access Visualizza/Apri |